Breaking new ground, Comphya, a medical device company headquartered in Lausanne, Switzerland, revealed a significant milestone: the triumphant implantation of an advanced battery-powered device designed to reinstate erectile function.
Comphya has pioneered the development of CaverSTIM, an implantable innovation that stands as the inaugural device catering to patients grappling with erectile dysfunction resistant to oral medications.
This specific patient cohort encompasses individuals who have endured spinal cord injuries and those who have undergone prostate removal surgery, recognized as post-prostatectomy patients.
This remarkable achievement unfolded at the Royal Melbourne Hospital (RMH) located in Melbourne, Australia. On August 3, Dr. Phil Dundee, a Consulting Urologist at RMH and Clinical Director at the Australian Prostate Centre (APC), conducted the triumphant procedure.
Dr. Dundee articulates, “Participating in this cutting-edge innovation is genuinely thrilling, especially given our awareness that this treatment has the potential to revolutionize the lives of countless patients worldwide.”
The inaugural clinical safety trial for this pioneering treatment materialized as a collaborative endeavor involving the APC, RMH, and Comphya SA.
Comphya’s Solution
Presently, individuals grappling with erectile dysfunction often turn to intrapenile injections or penile implants as their sole available treatment alternatives. Nevertheless, these approaches are recognized for their discomfort, complications, and antiquated nature.
This is precisely where Comphya’s patented solution steps in, presenting an unparalleled and advanced remedy for erectile dysfunction. The Swiss enterprise’s principal mission revolves around reinstating physiological sexual function and elevating the quality of life for a substantial segment of the male population desperately seeking such innovative solutions.
About the CaverSTIM
CaverSTIM constitutes a “neurostimulation” apparatus consisting of an implantable pulse generator (IPG). This device encompasses a rechargeable battery and electronic components responsible for generating an electrostimulation signal.
Surgically embedded within the pelvic cavity, the device springs to action, reinvigorating the nerves pivotal for facilitating penile erection.
Once implanted in the lower abdomen, the IPG is governed remotely by external controllers.
The clinician controller empowers medical experts to fine-tune and tailor the system’s parameters to accommodate the distinct requirements of each patient.
On the other hand, the patient controller puts the control in the hands of the individual, enabling them to activate the device and initiate a penile erection.
Rodrigo Fraga-Silva, CEO and Co-founder of Comphya SA, expresses, “As we inaugurate this clinical trial, we mark the culmination of our team’s unwavering dedication and painstaking efforts in bringing to fruition our distinctive CaverSTIM system.”
